Skip to Content

Mifepristone Disease Interactions

There are 6 disease interactions with mifepristone:


Mifepristone (Includes mifepristone) ↔ organ transplant

Severe Potential Hazard, High plausibility. Applies to: Organ Transplant

Mifepristone is contraindicated in patients with serious medical conditions, such as patients requiring treatment with systemic corticosteroids for immunosuppression after organ transplantation. Mifepristone antagonizes the effects of glucocorticoids.


Mifepristone (Includes mifepristone) ↔ vaginal bleeding

Severe Potential Hazard, Moderate plausibility. Applies to: Endometrial Dysplasia, Abnormal Uterine Bleeding, Bleeding Associated with Coagulation Defect

Mifepristone is contraindicated in women with unexplained vaginal bleeding, and women with endometrial hyperplasia with atypia or endometrial carcinoma, as it promotes endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and vaginal bleeding. It should also be used with caution in women with hemorrhagic disorders or those receiving anticoagulation therapy.


Mifepristone (Includes mifepristone) ↔ cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease, Heart Disease

Mifepristone does not reduce serum cortisol levels, and elevated cortisol levels might activate mineralocorticoid receptors which are expressed in cardiac tissue. Caution should be used in patients with underlying heart conditions, including heart failure and coronary vascular disease.


Mifepristone (Includes mifepristone) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

There is limited information on the safety of mifepristone in patients with mild to moderate hepatic impairment, hence the manufacturers recommend that the maximum dose should not exceed 600 mg per day. The use of mifepristone is not recommended in patients with severe hepatic disease as the pharmacokinetics in these patients have not been studied.


Mifepristone (Includes mifepristone) ↔ long QT

Moderate Potential Hazard, Moderate plausibility. Applies to: Long QT Syndrome

Mifepristone prolongs the QTc interval in a dose-related manner. There is little or no experience with high exposure, concomitant dosing with other QT- prolonging drugs, or potassium channel variants resulting in long QT interval. Caution and monitoring is advised if used in patients with long QT. To minimize risk, the lowest effective dose should always be used.


Mifepristone (Includes mifepristone) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No change in the initial dose of mifepristone is needed for renal impairment; but the manufacturers recommend that the maximum dose should not exceed 600 mg per day in these patients.

Mifepristone drug interactions

There are 778 drug interactions with mifepristone

Mifepristone alcohol/food interactions

There is 1 alcohol/food interaction with mifepristone

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.